Dr. Luis Villacorta, General Director, Dr. Sebastián Yurrita, Human Genetics and Genomics, Director of the Genetic laboratory and Co-FounderCo-founded by Dr. Sebastián Yurrita, director of the genetic laboratory and expert in human genetics and genomics, the company has redefined how early detection and precision medicine are delivered across the region. By harnessing cutting-edge technologies and tailoring solutions to the unique challenges of Latin American healthcare systems, BIOTI has built a reputation for innovation, accessibility, and life-saving impact. To achieve this, BIOTI is leveraging advanced genetic testing and molecular diagnostics to detect cancer years before tumors develop.
“By revealing cancer early and guiding the right treatment, we give patients peace of mind, better survival chances, and protection from the crushing costs of late-stage care,” says Yurrita.
The results of early detection speak volumes. BIOTI’s advanced genetic techniques can even project risks decades into the future, enabling physicians to select the most effective drug therapies for each unique case. Another hallmark of the company’s work is the breadth of its diagnostic capabilities. BIOTI offers more than 800 different genetic tests that cover fields ranging from oncology and pediatrics to cardiology, neurology, endocrinology, rheumatology, gynecology, and nutrition.
Rather than relying on years of trial-and-error diagnostics, it enables physicians to identify a patient’s condition with a single comprehensive test. This saves valuable time, reduces healthcare costs, and allows for rapid, accurate treatment. Importantly, BIOTI has also made affordability a core part of its mission, recognizing that equitable access to genetic testing is essential in a region where healthcare inequality remains a pressing challenge.
-
By bridging the gap between innovation and accessibility, we are enabling earlier interventions, reducing treatment burdens, and offering patients something once scarce in the fight against cancer—time and hope.
Among the advanced tools BIOTI promotes, liquid biopsy has become especially significant. This noninvasive technique, which relies on a simple blood sample, can detect circulating tumor cells even when surgical biopsies are not possible. BIOTI encourages its use because it allows physicians to spot cancer at earlier stages, identify metastasis, and define treatment strategies with far less risk and discomfort for patients.
In one striking case, BIOTI’s liquid biopsy revealed that a 55-year-old woman with breast mastitis and suspected bone lesions actually had early-stage breast, thyroid, and bone cancer driven by a single mutation. This insight enabled her physicians to intervene quickly and effectively, transforming a potentially dire prognosis into a manageable treatment path.
The company’s commitment to staying at the cutting edge of biotechnology is reflected in its global collaborations. BIOTI maintains close ties with laboratories in the U.S., Spain, Germany, India, China, and across Latin America, ensuring that its practices are informed by the latest scientific advances. By continually integrating emerging innovations, the company ensures that patients in the region gain access to diagnostic and therapeutic tools that rival the most advanced healthcare systems worldwide.
Looking to the future, BIOTI envisions genetics as a cornerstone of modern medicine, not confined to hereditary conditions but as a universal tool for diagnosis and prevention.
By bridging the gap between innovation and accessibility, BIOTI enables earlier interventions, reduces treatment burdens, and offers patients something once scarce in the fight against cancer: time and hope.
Cancer Preventive Testing Service Info
Why is BIOTI recognized among Top Cancer Preventive Testing Services providers?
BIOTI is recognized in Cancer Preventive Testing Services for its advanced genetic screening approach that evaluates hereditary cancer risk using next-generation sequencing (NGS). Its OncoRisk panel analyzes over 110 genes associated with multiple cancer types, helping identify inherited susceptibility before disease onset. This early-risk detection model positions its Cancer Preventive Testing Services within the growing field of predictive oncology focused on prevention rather than late-stage diagnosis.
What differentiates BIOTI in Cancer Preventive Testing Services?
A defining differentiator for BIOTI in Cancer Preventive Testing Services is its broad multi-gene analysis approach combined with high-resolution genomic sequencing. Instead of testing for a single mutation, it evaluates complex genetic variations including deletions, duplications and rearrangements across a wide cancer-associated gene panel. This allows a more complete understanding of hereditary risk profiles, strengthening its role in preventive cancer genomics.
How does BIOTI support early detection and risk assessment for cancer?
BIOTI supports early detection through Cancer Preventive Testing Services that identify genetic predispositions in asymptomatic individuals. Its OncoRisk test is designed for people with family history of cancer or those seeking proactive health insights. By analyzing inherited mutations linked to cancers such as breast, colon, prostate and ovarian cancer, it enables earlier clinical monitoring and preventive decision-making strategies.
How do Cancer Preventive Testing Services from BIOTI improve personalized healthcare?
Cancer Preventive Testing Services from BIOTI improve personalized healthcare by converting genomic data into actionable risk insights. Instead of a one-size-fits-all approach, the test identifies individual susceptibility patterns that can guide lifestyle changes, surveillance schedules and medical consultations. This supports a more proactive healthcare model where intervention can be planned before disease development.
What role does next-generation sequencing play in BIOTI’s testing approach?
Next-generation sequencing is central to Cancer Preventive Testing Services at BIOTI, enabling high-throughput analysis of multiple genes in a single test. This technology allows detection of subtle genetic variations across exonic and intronic regions, improving diagnostic depth and accuracy. The use of NGS ensures that even rare or complex mutations linked to hereditary cancers can be identified efficiently.
Why are Cancer Preventive Testing Services from BIOTI important in modern healthcare?
Cancer Preventive Testing Services from BIOTI are important because they shift cancer care from reactive treatment to proactive prevention. By identifying genetic risks early, individuals and clinicians can adopt monitoring strategies that reduce late-stage diagnosis rates. This aligns with the broader trend in precision oncology, where prevention and early detection significantly improve survival outcomes and long-term health planning.
